Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
June 04, 2021 09:08 ET | Source: Iovance Biotherapeutics, Inc. 86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune…

























